NCT01868477 - Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

March 22, 2017

Study Completion Date

April 5, 2017

Conditions

Low and Int 1-risk Myelodysplastic Syndrome

Interventions

DRUG

Deferasirox DFX, DT

provided as dispersible tablets for oral use in 125 and 250, 500 mg

DRUG

Erythropoietin alpha

DRUG

Deferasirox DFX, FCT

provided as film-coated tablet for oral use in 90, 180, 360 mg strengths

Trial Locations (30)

12203

Novartis Investigative Site, Berlin

17007

Novartis Investigative Site, Girona

18107

Novartis Investigative Site, Lütten Klein

22000

Novartis Investigative Site, Sidi Bel Abbes

31000

Novartis Investigative Site, Oran

40225

Novartis Investigative Site, Düsseldorf

51000

Novartis Investigative Site, Guangzhou

89124

Novartis Investigative Site, Reggio Calabria

97080

Novartis Investigative Site, Würzburg

100730

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

310003

Novartis Investigative Site, Hangzhou

610041

Novartis Investigative Site, Chengdu

C1425DND

Novartis Investigative Site, CABA

B1900AWT

Novartis Investigative Site, La Plata

V6Z1Y6

Novartis Investigative Site, Vancouver

L8V 5C2

Novartis Investigative Site, Hamilton

M4N 3M5

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Nanjing

01307

Novartis Investigative Site, Dresden

09126

Novartis Investigative Site, Cagliari

00161

Novartis Investigative Site, Roma

06351

Novartis Investigative Site, Seoul

08916

Novartis Investigative Site, Badalona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

413 45

Novartis Investigative Site, Gothenburg

SE-581 85

Novartis Investigative Site, Linköping

SE 971 80

Novartis Investigative Site, Luleå

SE-141 86

Novartis Investigative Site, Stockholm

OL1 2JH

Novartis Investigative Site, Oldham